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Abstract
In nature, B cells produce surface immunoglobulin and secreted antibody from the same immunoglobulin gene via
alternative splicing of the pre-messenger RNA. Here we present a novel system for genetically programming B cells to direct
the simultaneous formation of membrane-bound and secreted immunoglobulins that we term a ‘‘Molecular Rheostat’’,
based on the use of mutated ‘‘self-cleaving’’ 2A peptides. The Molecular Rheostat is designed so that the ratio of secreted to
membrane-bound immunoglobulins can be controlled by selecting appropriate mutations in the 2A peptide. Lentiviral
transgenesis of Molecular Rheostat constructs into B cell lines enables the simultaneous expression of functional b12-based
IgM-like BCRs that signal to the cells and mediate the secretion of b12 IgG broadly neutralizing antibodies that can bind and
neutralize HIV-1 pseudovirus. We show that these b12-based Molecular Rheostat constructs promote the maturation of
EU12 B cells in an in vitro model of B lymphopoiesis. The Molecular Rheostat offers a novel tool for genetically manipulating
B cell specificity for B-cell based gene therapy.
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Introduction
B cells are responsible for the production of antibodies in
response to foreign antigens [1]. The ability to manipulate the
antigen specificity of B cells and that of the antibody produced by
these cells could be useful for achieving immunization against
deadly pathogens such as HIV. In this paper, we describe a novel
system for simultaneously expressing IgM-like BCRs and IgG
antibody. The system is designed so that the ratio of surface and
secreted immunoglobulins can be controlled by appropriate
choices of mutations in the 2A peptide. We call this system
a ‘‘Molecular Rheostat’’.
B cells begin their life in the bone marrow as descendants of
the more primitive common hematopoietic stem and progenitor
cells. As these cells develop into B cells, they undergo sequential
RAG1/2-mediated DNA rearrangement of the heavy and light
chain immunoglobulin gene loci in a process called V(D)J
rearrangement. Cells that successfully complete this process and
assemble a functional B cell receptor (BCR) of the IgM isotype
on their surface are able to leave the bone marrow to continue
further development in the peripheral lymphoid compartments
[2,3]. The generation of the IgM BCR is central to B cell
development and function. It is both necessary for the normal
development of B cells [4,5,6], and sufficient for directing B cell
development. In transgenic animals. the provision of a pre-
rearranged IgM heavy chain and light chain transgene shuts
down the rearrangement of endogenous heavy and light chain
genes (allelic exclusion), and guides the ordered development of
functional B cells with specificity defined by the transgene [7,8].
These observations highlight the importance of the IgM BCR in
B-cell biology and suggest that any artificial molecule that
functions as a BCR would need to mimic IgM for it to be able to
direct B-cell development.
The mature B cells patrol the body in the general and
lymphatic circulations, using their BCRs as antigen sensors.
When a cognate antigen engages the BCR, the B cell becomes
activated and enters into a germinal center reaction in the
lymph node or spleen in a dance of mutual activation with T
cells; this process leads to further development into memory B
cells or differentiation into antibody-producing plasma cells. The
memory B cells will provide a more rapid and higher quality
antibody response in the future when the same antigens are
encountered again. The plasma cells produce antibodies against
the inciting antigens, which leads to their eventual clearance
from the body [1]. As B cells differentiate into plasma cells, they
switch from producing the membrane-bound IgM BCR to
making a soluble, secreted antibody. The genomic machinery
for effecting the switch is complex and involves alternative-
splicing of the heavy-chain pre-mRNA [9,10,11,12,13]. The
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switch replaces the hydrophobic amino acids that form the
trans-membrane anchor with a hydrophilic tail that enables the
secretion of the BCR as free antibody. The antibody retains the
same specificity and isotype as the BCR.
Initially we attempted to create such a switchable expression
system by exploiting the regulated alternative-splicing pathway of
the heavy chain locus in B cells. That approach proved to be
difficult due to the size of the locus (,1 Mbp), the challenges of
Figure 1. Simultaneous production of IgM-like BCR and secreted IgM using mutant 2A peptides. (A) Schematic representation of the IgM
version of the Molecular Rheostat Immunoglobulin constructs. Shown at the top is the design of the heavy chain constructs, containing a secreted
IgM heavy chain linked via a 2A element to the transmembrane region (41 aa inclusive of the C-terminus) of the membrane form of the IgM heavy
chain. 2A: location of self-cleaving 2A elements. See (B), (C), and Table 1 for the specific 2A peptides and their sequences. Shown at the bottom is the
light chain construct, furnishing the b12 k light chain. CMVp: CMV promoter. LTR: long terminal repeat. MH and EEK promoters: internal B cell specific
promoters from human IgM heavy and k light chain loci, respectively. b12 m heavy chain: IgM heavy chain with variable region corresponding to that
of the b12 broadly neutralizing antibody. (B) IgM surface staining of 293T cells co-transfected with the same amount of the IgM Molecular Rheostat
constructs (heavy chain to light chain in 1:1 ratio by mass) together with a third construct expressing human Iga and Igb. The cells were harvested 48
hours post-transfection. All IgM Molecular Rheostat constructs produced surface IgM. White: Membrane-bound IgM control. Blue: Molecular Rheostat
Constructs. Gray: GFP control. (C) IgM ELISA of supernatants of transfected cells. The constructs expressing different 2A mutants produced different
amounts of secreted IgM. IgM: membrane-bound IgM control.
doi:10.1371/journal.pone.0050438.g001
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employing RNA alternative splicing in a lentiviral vector context,
and the complexity of the natural alternative-splicing system in B
cells. Therefore, we sought to develop a simplified, synthetic
system that, while not fully switchable, still enables the simulta-
neous expression of the secreted and membrane-bound BCR at
a defined and controllable ratio. This Molecular Rheostat system
uses mutant self-cleaving 2A peptides to achieve control over the
relative amounts of secreted and membrane-bound immunoglo-
bulins.
2A peptides are ‘‘self-cleaving’’ peptides that are derived from
viruses [14,15]. They are involved in the processing and
expression of polyproteins. Mechanistically, these peptides do
not really undergo a ‘‘self-cleaving’’ event in the sense of breaking
a pre-existing peptide bond; rather the presence of the 2A element in
the mRNA causes the translating ribosome to undergo an intra-
ribosomal, translational termination-and-restart event during the
synthesis of the nascent polypeptide chains. The peptide bond
between the first and second polypeptide deriving from the same
mRNA is in fact not formed during translation. As a result, when
these two polypeptides are liberated from the ribosome, they
appear as two separate proteins [16,17,18]. Because the apparent
effect is as if a single polypeptide had been cleaved by an enzyme
post-translationally into two separate polypeptides, for consistency
with their historic description, we will still refer to 2A peptides as
‘‘self-cleaving’’ peptides, even though in reality they mediate
a ribosomal stop-and-restart event, referred to as a ‘‘StopGo’’
action of the 2A element [19].
Several 2A peptides appear to have near 100% cleavage
efficiency in their native contexts, but they can be made to cleave
at lower efficiencies when they are mutated at key amino acid
residues or introduced into non-native sequences [20,21,22]. By
engineering the peptides with reduced efficiency of cleavage, we
show that we can control the relative amounts of co-expressed
BCR and antibody by using different mutant 2A peptides. The
different choices of the 2A peptides are like the different settings of
a rheostat, allowing one to select, or tune, the relative amounts of
secreted and membrane-bound protein that the constructs pro-
duce. Thus we call the system a ‘‘Molecular Rheostat’’ for
controlling gene expression, and the constructs, Molecular
Rheostat constructs.
Materials and Methods
Constructs
The first-generation IgM Molecular Rheostat constructs re-
quired two vectors. The light chain vector was made by cloning
a b12 k light chain into the FEEKW vector. The heavy-chain
variable region of the b12 IgG antibody (from Dr. Gary Nabel,
NIH) was grafted onto a secretory version of the human IgM gene
cloned from a BAC containing a partial human heavy chain locus.
The resulting secretory form of the IgM heavy chain was then
joined via 2A elements to the IgM trans-membrane anchor
(corresponding to the last 41 aa from the C-terminus of the
membrane-bound form of the human IgM). These heavy chain
genes were then cloned into the FMHW vector. The FEEKW and
FMHW vector each contains a human k light chain and heavy
chain promoter, respectively, and were described by Luo et al.
previously [23]. See Figure 1A for a schematic.
The chimeric IgG/M Molecular Rheostat constructs were
created by cloning the EEK or MH promoters, the b12 light and
heavy chains, the 2A sequences, and an the 39 region of the human
IgM BCR gene corresponding to the last 41 amino acids into
either a pHAGE2 or pHAGE6 lentiviral vector. Both are third-
generation, self-inactivating lentiviral vector backbones based on
the pHRST [24,25]. See Figure 2A for a schematic.
Transfections
293T cells were grown to 50–75% confluence on 30 cm dishes
and were transfected in 15 ml D10 media (DMEM plus 10% heat-
inactivated fetal bovine serum, supplemented with 20 mM L-
glutamine, 1000 IU/ml penicillin, and 1000 mg/ml streptomycin,
filtered through a 0.22 mm PES membrane bottle-top filter) for
24 h. The transfections used the TransIT-293 reagent (Mirus Bio,
Madison WI) or BioT (Bioland Scientific, Paramount CA)
according to manufacturer’s instructions, using a total of 40 mg
DNA.
Lentiviral Vector Production
293T cells were transfected with lentiviral vectors. After 24 h
of incubation, the supernatant was pipetted off the cells and
filtered through a 0.22 mm PES membrane bottle-top filter into
a collection bottle. 15 ml of fresh D10 media was then filtered
through the bottle-top filter into the collection bottle to reduce
virus waste from supernatant that the filter absorbed. The
collected supernatant was stored at 4uC, and 30 ml of fresh D10
media was added to the dish. This collection process into the
same collection bottle was repeated 4 to 5 additional times at
12 h intervals. All of the collected supernatant was centrifuged at
10000 rpm for 12–24 h at 4uC to pellet the virus, and the
supernatant was poured off the pellet. The pellet was re-
suspended in 500–1000 mL DMEM media (for 293T transduc-
tions) or RPMI media 1640 (for OCI-Ly7 or EU12 transduc-
tions) and incubated on ice at 4uC for 12 h.
Lentiviral Transductions
0.5–16106 293T, OCI-Ly7, or EU12 cells were suspended in
1 mL of D10 media for 293T transductions or C10 media (RPMI
1640 plus 10% heat-inactivated fetal bovine serum, supplemented
with 25 mM b-mercapto-ethanol, 1000 IU/ml penicillin, and
1000 mg/ml streptomycin, filtered through a 0.22 mm PES
membrane bottle-top filter) for OCI-Ly7 or EU12 transductions
in 12 well plates, and 400–600 mL of virus re-suspensions or
dilutions thereof was added to each well. 10 mg/mL polybrene
(Millipore, Billerica, MA) was added so that the final polybrene
concentration was 10 mg/mL in each well. The transductions were
incubated for 24 h before the cells were passaged.
The EU12 cell line was a kind gift from Dr. Zhixin Zhang
(University of Nebraska Medical Center, Omaha, NE) and Dr.
Max Cooper (Emory University, Atlanta, GA), and was described
in detail by Zhang et al. [26]. The OCI-Ly7 B-cell line was kindly
provided by Dr. Louis M. Staudt (National Cancer Institute, NIH,
Bethesda, MD), and was originally described by Tweeddale et al.
[27].
Cell Line
The 293T-Igab cell line was created by infecting 293T cells
(purchased from ATCC) with a lentivector carrying the Iga and
Igb genes using the lentiviral transduction procedure described
above.
Tissue Culture
293T and 293T Ig-ab cells were grown in D10 media. The cells
were passaged 1:5 every other days. OCI-Ly7 and EU12 cells were
grown in C10 media. The cells were passaged 1:5–1:10 every
other day to maintain a density between 105–106 cells/ml.
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Flow Cytometry
For flow cytometric analysis, cells were first washed in PBS with
2% FBS, and then stained with combinations of the following
antibodies: anti-human-IgG-APC (BD Pharmingen, San Diego,
CA), anti-human-IgG-PE (BD Pharmingen), anti-human-IgM-
PE/Cy5 (BD Pharmingen), anti-CD10-PE (Biolegend, San Diego,
Figure 2. Screening Molecular Rheostat construct library for simultaneous expression of chimeric IgG/M BCR and secreted IgG. (A)
Schematic representation of the chimeric b12 IgG/M Molecular Rheostat constructs. The light chain and each of the chimeric heavy chains were
combined into single constructs co-expressing the light chain and the chimeric heavy chain. The light and heavy chains are joined by another 2A
peptide linker (denoted F2Aopt). 2A: location of mutant self-cleaving 2A elements. See (B), (C), and Table 1 for the specific 2A peptides screened and
their sequences. 2Aopt: optimized 2A element with a furin cleavage site at 59 end. CMVp: CMV promoter. LTR: long terminal repeat. EEK: internal B cell
specific promoter. b12 c heavy chain: IgG heavy chain with the variable region corresponding to that of the b12 broadly neutralizing antibody. (B)
Surface staining for human IgG. 293T- Igab cells were transfected with the same molar amount of chimeric IgG/M Molecular Rheostat constructs, and
analyzed for the expression of surface IgG by flow cytometry. All constructs produced surface-bound chimeric IgG/M BCR detected as human IgG.
Green: Molecular Rheostat Constructs. Red: Secretory IgG (L+H) control. (C) IgG ELISA of supernatants of transfected cells. Different Molecular
Rheostat constructs produced different amounts of secreted b12 IgG. FUGW: GFP containing vector control. L+H and H+L: secretory b12 IgG controls;
H+L has the light chain in the first position and heavy chain in the second position; L+H is in the opposite order.
doi:10.1371/journal.pone.0050438.g002
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CA). The cells were then analyzed on a BD FACSCalibur flow
cytometer.
Cell Sorting
Cells were prepared as in flow cytometric analysis and were
sorted with the assistance of Sylvia Chavira at the University of
Southern California’s Clinical Pathology Laboratory using a Mo-
Flo FACS cell sorter.
Calcium Flux Assay
Calcium flux measurements were made using the protocol given
by Bondada et. al. [29], with the following modifications: cells were
washed, pelleted, and resuspended in Dye Loading Buffer (HBSS
with Ca2+ and Mg2+ plus 4% 100mM probenecid, 2% 1 M
HEPES buffer, and 1% heat-inactivated fetal bovine serum) and
were incubated with 4 mg/mL Fluo-3 AM and 1 mg/mL FuraRed
AM dyes in the presence of 0.02% (w/v) pluronic F-127 for 30 m.
The cells were again washed, pelleted, and resuspended in Dye
Loading Buffer and were kept at room temperature until they were
analyzed on a BD FACSCalibur flow cytometer equipped with
a circulating 37uC water bath on the sample port. During analysis,
cells were stimulated with goat F(ab’)2 anti-human IgG c Fc-
specific antibodies (Invitrogen, Carlsbad, CA) or with goat F(ab’)2
anti-human IgM m Fc-specific antibodies (Southern Biotech,
Birmingham, AL) and a ratiometric measurement between the
Fluo-3 AM and FuraRed AM dye channels was made for 512 s.
On some samples, ionomycin controls were performed to calibrate
the dynamic signaling range.
ELISA
Supernatants from cultured cells were analyzed using Human
IgG ELISA Quantitation Set (Bethyl Laboratories, Montgomery,
TX) according to manufacturer’s instructions.
Surface Plasmon Resonance gp120 Binding Assay
The Surface Plasmon Resonance (SPR) gp120-binding assays
were performed as previously described by Klein et al. [28]., with
the following modifications: All experiments were done in-house.
b12 antibody supernatants were produced from transfection of
293T cells.
In Vitro Neutralization Assay
In vitro neutralization assays were performed as previously
described by West et. al. [30], with the following modifications: All
experiments were done in-house. Pseudoviruses were produced by
co-transfecting HEK293T cells with an Env SF162 expression
plasmid and a replication-defective backbone plasmid, PSG3mi-
nusEnv. Each mutant Fc and unmodified fragment version of b12
samples was tested in duplicates.
Results
IgM Molecular Rheostat Immunoglobulin Genes Mediate
Co-Expression of IgM-Like BCR and Secreted IgM
Antibody
As a pilot experiment to test whether the mutated 2A peptides
can mediate co-expression of surface and secreted immunoglobu-
lins, we constructed the first-generation of Molecular Rheostat
Immunoglobulin genes by joining the secreted version of the b12
IgM heavy chain to the transmembrane domain of the IgM BCR
via a mutated 2A peptide. The transmembrane domain is defined
as the M1 and M2 exons from the human IgM locus and
comprises the last 41 amino acids of the membrane bound IgM
BCR (Figure 1A). We call these ‘‘IgM Molecular Rheostat’’
constructs. We chose the wild type F2A and two mutant peptides
as well as another F2A-like element derived from a silk-worm
virus, based on previous work by Donnelly et al. [20], in which
they observed reduced cleavage efficiencies when certain muta-
tions are introduced. The four mutants we chose are designated
F2A, F2A(3), F2A(14), and I2A(2). See Table 1 for the nomen-
clature and the amino acid sequence for each of the 2A elements.
We cloned these IgM Molecular Rheostat genes into a lentiviral
vector plasmid (FMHW), which also doubles as a mammalian
expression vector under the control of a CMV promoter
(Figure 1A). We co-transfected these heavy chain vectors together
with a separate vector carrying the b12 light chain (FEEKW-
b12L) and a mammalian expression vector carrying the human
Iga and Igb genes (phIgab) into 293T cells. The FMHW vector
backbone and the related FEEKW were previously described by
Luo et al. [23]. Briefly, both are lentiviral vectors that contain
promoters derived from B-cell-specific genes. The FMHW vector
carries the MH promoter, which is composed of a human
immunoglobulin heavy chain variable region promoter coupled to
the m-intronic enhancer. The FEEKW vector carries the EEK
promoter, which is composed of the human k light chain promoter
coupled to k light chain enhancer elements. We analyzed the
transfected cells and their supernatants by flow cytometry and
human IgM ELISA 48 hours later. All transfected cells showed
surface expression of the IgM Molecular Rheostat BCR and
secreted IgM into their supernatants (Figure 1B and 1C).
Chimeric IgG/M Molecular Rheostat Constructs Mediate
Simultaneous Expression of chimeric IgG/M BCRs and
Secreted IgG Antibody
We next attempted to adapt the Molecular Rheostat format to
the production of an IgG antibody in an effort to mimic an
isotype-switched secretory IgG while preserving the signaling
Table 1. Nomenclature and amino acid sequences of
different 2A peptides.
2A Mutant Mutation Type Amino Acid Sequence
F2A Wild-type QLLNFDLLKLAGDVESNPGP
F2A(21) 1aa N-terminal deletion LLNFDLLKLAGDVESNPGP
F2A(22) 2aa N-terminal deletion LNFDLLKLAGDVESNPGP
F2A(23) 3aa N-terminal deletion NFDLLKLAGDVESNPGP
F2A(24) 4aa N-terminal deletion FDLLKLAGDVESNPGP
F2A(25) 5aa N-terminal deletion DLLKLAGDVESNPGP
F2A(26) 6aa N-terminal deletion LLKLAGDVESNPGP
F2A(27) 7aa N-terminal deletion LKLAGDVESNPGP
F2A(3) Point mutation QLLNFDLLKLAGDVQSNPGP
F2A(11) Point mutation QLLNFDLLKLAGDVEINPGP
F2A(14) Point mutation QLLNFDLLKLAGDVESEPGP
F2A(19) Point mutation QLLNFDLLKLAGDVESNPAP
I2A(0) Wild-type TRAEIEDELIRRGIESNPGP
I2A(1) Point mutation TRAEIEDELIRAGIESNPGP
I2A(2) Alternative codon TRAEIEDELIRRGIESNPGP
I2A(3) Point mutation TRAEIEDELIRRGIESNPAP
doi:10.1371/journal.pone.0050438.t001
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properties of an IgM, which is required for normal B cell
development. Furthermore, we wished to explore whether we
could manipulate the ratio of surface-bound to secreted immu-
noglobulins by making appropriate mutations in the 2A elements.
To test these ideas, we constructed a library of chimeric IgG/M
Molecular Rheostat Immunoglobulin genes, in which a complete
secretory b12 IgG is joined to the transmembrane anchor and the
intracellular domain of the IgM BCR via different 2A peptides
(Figure 2A). The library includes 2A peptides listed in Table 1.
To reduce the number of vectors that need to be transfected and
anticipating the need to use the vectors in the context of lentiviral
transduction, where it would be advantageous to work with a single
vector, we fused the b12 k light chain with the Molecular Rheostat
heavy chain transgene by joining the b12 k light chain to the b12
IgG heavy chain via a different F2A element, F2Aopt. F2Aopt is
codon-optimized for human expression and contains a furin
cleavage site before the 2A element.
Additionally, to ensure consistency of Iga and Igb expression
across the cells used to test the Molecular Rheostat constructs and
reduce the number of vectors that need to be transfected, we
engineered 293T cells that express human Iga and Igb by
repeatedly co-infecting 293T cells with two lentiviral vectors,
FUW-Iga and FUW- Igb, which carry the Iga and Igb transgenes,
respectively, under the control of a ubiquitin C promoter. The
resulting cells are denoted 293T-Igab cells.
We transfected the library of chimeric IgG/M Molecular
Rheostat constructs into the 293T-Igab cells, and 48 hours later
analyzed the cells and their supernatants for surface IgG by flow
cytometry and secreted IgG by ELISA, respectively. All trans-
fected cells showed surface expression of the IgG/M Molecular
Rheostat BCR (detected as surface IgG because the extracellular
portion of the chimeric BCR is made up of the heavy chain of IgG)
and secreted IgG into the culture supernatant (Figure 2B and 2C).
Significantly, while the surface expression of the IgG/M Molec-
ular Rheostat BCR appears comparable across all constructs,
there is a range of levels of secreted IgG. This suggests that the
different Molecular Rheostat constructs could be used to produce
a range of ratios of surface to secreted immunoglobulins by
judicious choices of the 2A peptide mutants.
Chimeric IgG/M Molecular Rheostat Constructs Mediate
Expression of a Range of Ratios of Surface BCR to
Secretory IgG in the Human B-Cell Line OCI-Ly7
To validate the results that the chimeric IgG/M Molecular
Rheostat constructs can mediate a range of expression ratios of
surface BCR to secreted antibodies in human B cells, we used
lentiviral vectors to deliver the constructs into the OCI-Ly7 B- cell
line, which expresses an endogenous IgM BCR on its surface and
therefore should possess the necessary machinery (such as Iga and
Igb co-receptors) for BCR surface expression. To provide an
independent marker of lentiviral transduction other than the
expression of the Molecular Rheostat Immunoglobulins, we
constructed a lentiviral vector, pHAGE2-EEK-IRES-ZsGreen,
which contains an Internal Ribosomal Entry Site (IRES) driving
a ZsGreen fluorescent protein gene. Based on the results in
Figure 2B, we selected six of the IgG/MMolecular Rheostat genes
and cloned them into the first position (before the IRES-ZsGreen)
of the pHAGE2-EEK-IRES-ZsGreen vector. We then infected
OCI-Ly7 cells with the chimeric IgG/M Molecular Rheostat
vectors at low MOI (, 0.1) to ensure that nearly every cell that
was infected had at most one copy of the transgene (Figure 3A). 48
hours after infection, we sorted out the ZsGreen positive cells and
allowed these cells to expand for another 48 hours. The cells and
supernatants were analyzed by flow cytometry and ELISA,
respectively (Figure 3B, left and right panels, respectively). The
different mutants produced a range of ratios of surface to secreted
immunoglobulins. Significantly, there is an inverse relationship
between the amounts of chimeric IgG/M Molecular Rheostat
BCR expressed on the surface of the cells vs. the amounts of IgG
antibody that was detected in the supernatants, indicating that the
mutant 2A elements could be used like a ‘‘rheostat’’, tuning the
ratios of surface to secreted immunoglobulins. This inverse
relationship is visualized by plotting the MFI (mean fluorescence
intensity) of surface IgG staining in the left panel and contrasting
this trend with the levels of secreted antibody production in the
right panel of Figure 3B. (See Figure S1 for original FACS
histograms of surface IgG staining.) Biasing the Molecular
Rheostat towards producing more surface receptors results in
a decrease in antibody secretion. Also notably, the rank order of
the relative amounts of surface BCR to secreted immunoglobulin
expression recapitulates what was observed from the transfection
experiment with 293T-Igab cells (see Figure 2B and C). For
example, from Figure 2B and C, F2A(-2) would be expected to
make more secreted IgG than F2A(-4), and this was indeed the
case when the constructs were expressed in the OCI-Ly7 B cell
line as shown in Figure 3B and C. Furthermore, F2A(-2) made less
surface Molecular Rheostat BCR than F2A(-4), as would be
expected if the F2A(-2) peptide mediated more efficient cleavage
than the F2A(-4) peptide. The library of mutant constructs
together constitutes a Molecular Rheostat that we can use to direct
tunable ratios of expression of surface BCR vs. secreted
immunoglobulin.
IgG/M Molecular Rheostat Constructs Produce Functional
b12 IgG/M Chimeric BCRs are Signaling Competent and
Bind to HIV gp120
To test whether the chimeric IgG/M BCRs were functional, we
developed a ratiometric Fluo-3/FuraRed calcium flux assay in
which anti-BCR crosslinking antibodies are used to examine
whether the BCRs are able to signal in the OCI-Ly7 B cells. We
chose two of the 2A peptides from the library, F2A, which cleaves
with high efficiency, and I2A(2), which does not cleave well. As the
ZsGreen protein interferes with the Fluo-3 calcium-sensitive dye
used in the assay, we cloned those two chimeric IgG/MMolecular
Rheostat genes into lentiviral vectors that do not have the IRES-
ZsGreen marker gene. Lentiviral infections of OCI-Ly7 B cells
with these vectors resulted in a variegated pattern of expression of
the BCRs. The vector containing the I2A(2) element showed
generally higher levels of surface BCR expression than F2A, as
expected. While both populations responded to BCR stimulation
using a control anti-IgM antibody (Southern Biotech, Birming-
ham, AB) and an anti-IgG antibody (Sigma, St Louis, MO), the
responses were detectable but modest (data not shown). We believe
the modest response was due to the effect of averaging the calcium
signals over the large range of surface expressions. To ensure we
have more homogenous populations for use in BCR stimulations,
we FACS sorted out the top 10% of IgG positive cells from each of
the populations (Figure 4B), and performed the calcium flux assays
on the sorted cells. The cells responded robustly to anti-BCR
stimulation (Figure 4A), with a dose-response correlating with the
levels of surface IgG/M Molecular Rheostat BCR expression and
the concentrations of anti-Ig used. The higher anti-IgG dose
(100 ug/ml) gave a stronger calcium signal than the lower dose
(20 ug/ml); the cells with more surface Molecular Rheostat BCR
expression also generated a stronger and more lasting response.
Additionally, to see whether the chimeric IgG/M BCR would
bind to HIV antigens, we co-stained the sorted OCI-Ly7 cells with
fluorescently labeled HIV gp120MN and anti-IgG, which re-
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spectively interact with the gp120-antigen-binding site of b12 and
the c heavy chain constant region of b12 IgG (Figure 4C). We
found that the Molecular Rheostat BCRs on the cells bound to
HIV gp120.
Chimeric IgG/M Molecular Rheostat Constructs Produce
b12 IgG Antibody that Neutralizes HIV Pseudovirus with
Same Potency as Unmodified b12 IgG
To determine whether secreted b12 IgG from the Molecular
Rheostat system can neutralize infectious virus, we performed an
in vitro pseudovirus neutralization assay using an Env SF162
pseudotyped HIV-1 pseudovirus on the TMZ-b1 reporter cell line
with supernatants from 293T cells transfected with several
different chimeric IgG/M Molecular Rheostat constructs accord-
ing to a protocol previously described by Klein et al. [28]. The
neutralization curves demonstrated that secreted Molecular
Rheostat b12 IgG antibodies neutralized the Env SF162
pseudovirus as potently as the control b12 IgG antibody (L+H),
with IC50 values nearly identical to that of the control b12 IgG
(Figure 5A). We also performed a surface-plasmon resonance
gp120-binding assay. The antibodies tested bound gp120 as well as
the control b12 IgG antibody, consistent with the neutralization
assay results (Figure 5B).
Expression of Chimeric IgG/M Molecular Rheostat
Immunoglobulins Promote Maturation of EU12 Cells in
an In Vitro Model of B Cell Development
The promotion of B cell development is one of the major
functions performed by the IgM BCR. It thus offers a stringent test
of BCR function. To test whether the chimeric IgG/M Molecular
Rheostat Immunoglobulin BCR can direct B cell development, we
adopted a model of human B cell development using the EU12 cell
system [26,29]. EU12 cells are derived from a B cell leukemia
patient; they are uniformly CD19+ but exist in a spectrum of
primitive (CD34+ and CD102, or CD34+ and CD10+) to more
mature (CD342 and CD10+, or CD342 and CD102) states.
These cells lack a functional BCR, but rarely an IgM BCR is
generated spontaneously and the cells proceed to acquire a more
mature phenotype.
We isolated early-stage, CD34+ EU12 cells by FACS sorting.
These cells were then transduced with lentiviral vectors carrying
chimeric IgG/M Molecular Rheostat constructs that give rise to
respectively low, intermediate, and high surface BCR expression.
A luciferase-carrying vector was used as a control. The cells were
allowed to expand, and 4 weeks after transduction the surface
expression of chimeric IgG/M Molecular Rheostat BCR and
maturation markers were analyzed by FACS (Figure 6). The EU12
cells transduced with Molecular Rheostat constructs tuned at
Figure 3. Inversely-related expression of b12 chimeric IgG/M BCR and secreted IgG mediated by mutant 2A peptides. (A)
Experimental design for measuring the expression of surface to secreted immunoglobulins by IgG Molecular Rheostat constructs. To establish that it
is possible to tune the ratio of surface to secreted immunoglobulins by making appropriate choice of mutations in the 2A peptide, select b12 IgG/M
chimeric constructs (based on the experiment with the 293T cells in Figure 2) were modified to include an additional ZsGreen fluorescent protein
gene driven by an IRES 39 of the heavy chain. OCI-Ly7 B cells were infected with at low MOI (, 0.1) with this library of constructs and the cells that
express the ZsGreen gene were sorted out by FACS. The cells were cultured for 24 hours post-sorting; the cells were analyzed by flow cytometry and
supernatants were taken for IgG ELISA. (B) Inverse relationship between surface expression of chimeric b12 IgG/M Molecular Rheostat BCRs and
secreted b12 IgG in the supernatants of sorted cells. NV: untransduced control. L+H: secretion only b12 control. The Molecular Rheostat constructs are
denoted by the mutant 2A elements they contain.
doi:10.1371/journal.pone.0050438.g003
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different levels of surface BCR vs. secreted antibody expression
showed the expected levels of surface BCR expression (F2A was
used for maximum secretion; F2A(11) for intermediate; F2A(19)
for maximal surface). Using ZsGreen as a measure of the amount
of gene expression from the entire cassette in each cell, the level of
chimeric IgG/M BCR expression correlated with the ZsGreen
expression level for each of the three Molecular Rheostat
constructs (Figure 6A). Gating on the highly expressing cells, we
Figure 4. Molecular Rheostat constructs generate functional chimeric IgG/M BCRs that signal and bind to HIV gp120. (A) To test
whether the chimeric b12 IgG/M BCRs were functional, the cells were stimulated in a ratiometric calcium flux assay under different stimulation
conditions. OCI-Ly7 B cells were infected with a library of chimeric b12 IgG/M Molecular Rheostat constructs that did not contain the IRES-ZsGreen
marker gene. 48 hours after infection, cells expressing high amounts of surface IgG by flow cytometry (top 5%) were sorted out. The sorted cells were
allowed to rest for 24 hours before anti-BCR stimulation. First column: response of endogenous IgM BCR to anti-IgM stimulation. Second column:
high dose (100 ug/ml) anti-IgG stimulation. Third column: low dose (20 ug/ml) anti-IgG stimulation. The BCR expression profiles of the cells at the
time of stimulation are shown in the left-most column: endogenous IgM expression (vertical) vs. surface IgG staining from chimeric IgG/M Molecular
Rheostat BCR (horizontal). Red: sorted cells expressing the Molecular Rheostat Immunoglobulins. Green: uninfected control cells. The results of anti-
IgG stimulations are shown as a panel on the right. First column: response of endogenous IgM BCR to anti-IgM stimulation. Second column: high
dose (100 ug/ml) anti-IgG stimulation. Third column: low dose (20 ug/ml) anti-IgG stimulation. (B) Anti-IgG and gp120MN labeling of sorted cells. Red
and Blue: I2A(2) and F2A Molecular Rheostat Immunoglobulin vector transduced cells, respectively. Green: untransduced control cells.
doi:10.1371/journal.pone.0050438.g004
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analyzed CD34 and CD10 expression by FACS. We found that
the cells that had been transduced with Molecular Rheostat
constructs chosen for higher surface BCR expression and less
secreted antibody had larger populations of cells that down-
regulated CD10 (Figure 6B). This provides further evidence that
the chimeric IgG/M BCRs were functional BCRs and were able
to promote maturation of B lineage cells.
Discussion
To provide a compact system for genetically manipulating the
BCR and antibody specificity of B cells with a lentiviral vector–
with the ultimate goal of B cell gene therapy– we created the
Molecular Rheostat system. With this system, we could direct
various ratios of simultaneous formation of membrane-bound and
secreted immunoglobulins by using appropriate mutant 2A ‘‘self-
cleaving’’ peptides. We term this a ‘‘Molecular Rheostat’’ because
it can be tuned by the choice of mutant 2A (Figure 7). This system
provides a synthetic approximation to the process of switching
through the evolved RNA alternative splicing mechanism, the
route naturally used to make membrane and secreted immuno-
globulins in B cells. That process is incompletely understood but
appears to require a longer sequence than could be put into
a lentiviral construct [9,10,12,13,30,31,32,33,34,35]. By fusing an
IgG to the membrane anchor of IgM through different mutant 2A
peptides, we constructed a library of chimeric IgG/M Molecular
Rheostat constructs and showed that the library of constructs
produced both membrane-bound BCR and secreted antibody at
controllable ratios. We also showed that the surface chimeric IgG/
M Molecular Rheostat BCRs thus produced signaled to B cells
and that these BCRs bound to HIV gp120 antigens. We showed
that the secreted version of b12 IgG produced by these constructs
also bound gp120 and neutralized HIV-1 pseudovirus equally as
well as unmodified b12 IgG. Finally, we provided evidence
suggesting that the chimeric BCR produced by the Molecular
Rheostat system can direct maturation of B cells using a cell line
model of B cell maturation. In EU12 cells transduced with vectors
carrying the Molecular Rheostat Immunoglobulins, we observed
downregulation of CD10, a sign of the maturation of the
progenitor cells upon the expression of the chimeric IgG/M
Molecular Rheostat BCRs. We note that this effect was dose
dependent, with greater size of the CD102/CD342 population
being observed in the cells that received the more surface-biased
Molecular Rheostat constructs. This suggested that the chimeric
IgG/M Molecular Rheostat BCRs were capable of directing the
maturation of these cells.
The development of a vector system for programming the
development of functional anti-HIV B cells from the hematopoi-
etic stem cells (HSCs) provided the original impetus for our work.
We envisioned transducing the HSCs with the lentiviral vector and
then transplanting the transduced HSCs back into at risk
individuals. The anti-HIV B cells that developed could then serve
as a life-long prophylaxis against HIV infection. While one might
imagine building such a vector for programming B cells by
combining the entire heavy chain and light chain loci into a single
vector, the heavy chain locus alone is , 1 Mb, too big to
incorporate into a lentiviral vector, which has a insert-carrying
capacity of , 10 kb, beyond which titers become too low to be of
practical use [36]. We attempted to reduce the size of the vector
‘‘payload’’ by removing the introns of the heavy chain locus,
except for the one required for the alternative splicing of the
secreted and transmembrane exons, but were not successful
because the resulting constructs did not splice correctly. We thus
created the Molecular Rheostat system to approximate the natural
system, incorporating the additional feature of expressing isotype-
switched IgG antibodies while maintaining the signaling properties
Figure 5. b12 IgG produced by Molecular Rheostat constructs neutralized Env SF162 pseudovirus and bound to GP120. (A) In vitro
neutralization assay against Env SF162 pseudovirus. The chimeric IgG/M Molecular Rheostat constructs were transfected into 293T cells and IgG in the
supernatants were purified using an affinity column. The purified IgG were used in the neutralization assay. The neutralization curves are nearly
identical for all mutant 2A constructs and the control b12 IgG (L+H). The IC50 values are indicated to the right of the graph. IgG b12: a batch of
previously purified b12 IgG included as a positive control for the assay. (B) Surface plasmon resonance (SPR) GP120 binding assay. Supernatants from
transfected 293T cells were diluted with media to the same IgG concentration and used in the SPR binding assay. The plot shows nearly identical SPR
traces for each of the two tested 2A mutant constructs and the control (L+H).
doi:10.1371/journal.pone.0050438.g005
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of an IgM transmembrane domain. Our results, presented in this
paper, suggest that the Molecular Rheostat system, which is small
enough to be introduced into cells with a lentiviral vector, could be
used to direct the in vivo maturation of anti-HIV B cells. To see
whether this approach could be used as prophylaxis against HIV
infections, a detailed characterization in animal models would be
needed.
The Molecular Rheostat system coupled with a B-cell specific
promoter (such as EEK or MH) can be used as a ‘‘gene therapy
vaccine’’ to direct in vivo development of an anti-HIV immune
system to produce broadly neutralizing anti-HIV antibodies. An
attempt to investigate gene therapy as prophylaxis against HIV by
vector-mediated delivery of broadly neutralizing antibody to
HSCs in a humanized mouse model was previously made by
Joseph et al. [37]. However, the antibody levels they were able to
achieve in vivo were low, likely because the system they used
contained only a secretory antibody lacking BCR function and
a non-B cell promoter. While the theoretical maximum levels of
antibody achieved with the Molecular Rheostat might be less than
an ideal, natural, alternative-splicing system due to the fixed
diversion of some antibody production capacity toward the
expression of surface BCRs, the Molecular Rheostat system, by
providing a membrane BCR, opens the possibility of harnessing
the enormous numerical amplification power of B-cell clonal
expansion following antigen encounter and the hugely upregulated
synthetic and secretory capacity of plasma cells that arise as a result
of B cell activation through the BCR. This will enable the
provision of high levels of circulating anti-HIV broadly neutral-
izing antibodies by taking advantage of two very powerful
amplification mechanisms of the natural immune system. In this
regard, the results from the EU12 and OCI-Ly7 cell experiments
are very promising – they show that so long as there are sufficient
surface levels of BCR expression, the specific choice of 2A mutants
is not that important in promoting B cell maturation or allowing B
cell function, since both the ‘‘intermediate’’ and ‘‘maximum
surface’’ contructs were able to promote B cell maturation and
both ‘‘high’’ and ‘‘low’’ surface mutants were able to generate
Ca++ signals to the B cells. This provides great flexibility in the
choice of mutants to use.
In this study, we used two B-cell derived promoters, MH and
EEK. In in vitro tests using cell lines, we found genes driven by
these promoters to be highly expressed in B-lineage cells but only
weakly in a non-B lineage cell line, 293T ([23] and unpublished
data). The use of B cell specific promoters would enable high level
expression from B cells, taking advantage of the natural clonal
expansion and amplification process following encounter with
Figure 6. Molecular Rheostat IgG/M BCRs promote downregulation of CD10 in EU12 cells. (A) CD34+ EU12 cells (early B cells) transduced
with IRES-driven ZsGreen expressing Molecular Rheostat constructs were analyzed by flow cytometry. Surface BCR levels correlate with ZsGreen
intensity. Cells transduced with Molecular Rheostat constructs tuned for higher surface expression showed more surface BCR expression with the
same ZsGreen expression. The red box shows ZsGreen gating. (B) Gating on high ZsGreen expression, CD10 and CD34 expression was analyzed. Cells
transduced with constructs that express higher surface IgG/M BCR levels show a greater extent of CD10 downregulation, suggesting that the
Molecular Rheostat BCRs are signaling to the cells and promoting maturation.
doi:10.1371/journal.pone.0050438.g006
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HIV antigens, and provides a fairly natural way to express
antibody genes. However, we believe that the system would still
work even if the promoters were not completely B-cell specific and
antibodies were secreted by some non-B lineage cells. If any
antibodies were produced by non-B lineage cells due to non-
specificity of the promoters, they would not inhibit anti-HIV B-cell
development in the bone marrow because there B-cell de-
velopment depends only on the presence of a functional BCR
and not on high levels of antigens (which would actually inhibit B
cell development). Minor non-specificity of the promoter giving
rise to additional antibodies could actually enhance protection
against HIV infection because they could provide a basal,
constitutive level of protection against low amounts of virus, while
the antigen-specific B cells would respond to the ‘‘breakthrough’’
viruses that surmounted the basal level of circulating antibodies.
The Molecular Rheostat system thus provides a robust means to
genetically program anti-HIV B cells.
In practice, the level of expression of a vector-delivered gene is
a function of many factors, including, importantly, copy number
variation and vector integration site effects as well as the choice of
promoters. Some transduced cells will receive more copies of the
transgene at more favorable chromosomal locations than others.
With the Molecular Rheostat system, clones of cells with good
surface expression will likely be preferentially selected to develop
in vivo because the natural process of B cell development favors
cells with good BCR expression. This will translate into the
selection of cells that are also able to produce higher levels of
secretory antibody because the ratio of surface to secreted
antibody is fixed by the choice of the F2A mutant. For this
reason, so long as only one F2A mutant is used in any given
individual, the clones of cells with the highest gene expression
levels (both surface expression and secretion) will be preferentially
selected. The goal then is to choose the 2A mutant that maximizes
secretion, as long as sufficient surface BCR expression is
maintained so that antigen-specific B cells are able to develop
from the bone marrow and respond to antigens. This could be
done in practice by screening the different mutants of the
Molecular Rheostat library in bone marrow transplant animal
models and selecting the 2A mutant that yielded the highest
antibody concentration while providing mature antigen-responsive
B cells.
In summary, the flexibility of being able to use a range of
mutants in the Molecular Rheostat library coupled with the choice
of strong B cell promoters (such as EEK and MH) makes it
a promising gene therapy approach to HIV prophylaxis. While we
used the b12 antibody in this work, a ‘‘cocktail therapy’’ approach
by using multiple anti-HIV broadly neutralizing antibodies in
separate vectors could increase the spectrum of coverage of the
system. With some slight modifications, this system of simulta-
neous BCR and IgG expression may also be used to manipulate B
cells to target other antigens.
The principle of using a library of mutant 2A peptides as
a Molecular Rheostat to mediate tunable simultaneous expression
of two different proteins are not limited to B- cell programming,
and may be applied to other contexts, such as the study of multi-
domain transcription factors, or the engineering of other
polyprotein expression systems, where a full-length protein and
a partially truncated one are required at controllable stoichiomet-
ric amounts. In gene therapy, an important problem is to track
cells that express a vector-delivered transgene–this is especially
important in the event of an adverse reaction. A particularly
interesting application of the Molecular Rheostat is to use it as
a ‘‘flag’’ to mark cells that express an exogenous soluble protein,
such as a soluble therapeutic antibody, by displaying a small
amount of the transgenic antibody on the surface. A version of the
Molecular Rheostat biased toward secretion with a small amount
of surface expression can be used to connect the soluble antibody
with a mutant IgM-transmembrane domain that mediates Iga-
and Igb-independent expression (e.g., the YS-VV mutant [38,39])
or another membrane anchor (e.g. the GPI-anchor signal of LFA-
3 [40]). Most of the antibody produced will be secreted, but a small
amount of the full-length antibody-anchor fusion will be expressed
Figure 7. A model of how the b12 IgG Molecular Rheostat Immunoglobulin system directs tunable simultaneous formation of
surface BCR and secreted IgG. By making an appropriate choice of the 2A peptide from the library, a specific ratio of secreted IgG and surface
chimeric IgG/M BCR can be achieved.
doi:10.1371/journal.pone.0050438.g007
Self-Cleaving 2A Peptides as a Molecular Rheostat
PLOS ONE | www.plosone.org 11 November 2012 | Volume 7 | Issue 11 | e50438
on the cell surface. This provides a compact way to mark the
transduced cells by displaying the transgenic antibody as a ‘‘flag’’
that can be easily recognized by either the antibody’s cognate
antigen, or an anti-idiotypic antibody against the transgenic
antibody. The cognate antigen or anti-idiotypic antibody coupled
to a marker molecule or a toxin can then be used to track or
eliminate the transgene-expressing cells. The Molecular Rheostat
is thus a versatile tool for protein engineering and gene therapy.
Supporting Information
Figure S1 FACS histograms of surface IgG expression of
OCI-Ly7 cells transduced with different Molecular
Rheostat constructs. Green: surface IgG expression from
different mutant 2A peptides in the Molecular Rheostat
Immunoglobulin genes. Red: control L+H contruct (secreted
antibody only). The plots are arranged in the same rank order as
that shown in Figure 3A.
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